Skip to content
Menu

Silence Therapeutics plc SLN

Full chart Compare
Set alert

Price alert · SLN

All alert types
19.81 USD 0.00 (+0.00%)

Regular-session close

19.81 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

19.80 Day range 19.83
4.30 52-week range 19.83
YTD
+225.82%
1 year
+211.97%

5D +0.01 (+0.05%)

19.8019.82MonTueWedThuFri19.81
Market cap
1.23B
Revenue (ttm)
456.00K
EPS (ttm)
-1.05
Shares out
62.20M
Forward P/E
-24.76
YTD return
+225.82%
1-year return
+211.97%
50-day average
15.15
200-day average
10.08
Enterprise value
984.67M
Volume
399.15K
Avg volume
2.41M
Open
19.81
Previous close
19.81
Day's range
19.80 – 19.83
52-week range
4.30 – 19.83
Beta
1.34
Analysts
Hold
Price target
19.75 (-0.3%)
Earnings date
Mar 4, 2027

Key statistics

Price / sales
2702.28
Price / book
5.73
Free cash flow
-25.65M
Total cash
247.66M
Total debt
87.00K
Return on equity
-35.58%
Short % of float
4.77%

Fundamental scorecard

5 of 25 checks passed on SLN’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SLN Revenue — quarterly 0
SLN Net income — quarterly -12.43M
SLN EPS — quarterly -0.24

Earnings

SLN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 4, 2027Dec 30, 2026-0.08833———
Nov 12, 2026Sep 30, 2026-0.26-0.24+0.02+7.69%
Aug 10, 2026Jun 30, 2026-0.13866-0.26-0.12-87.51%
May 7, 2026Mar 31, 2026-0.33-0.32+0.01+3.03%
Mar 5, 2026Dec 31, 2025-0.32-0.25+0.07+21.88%
Nov 6, 2025Sep 30, 2025-0.40-0.45-0.05-12.50%

Upgrades / downgrades

SLN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026HC Wainwright & Co.downBuyNeutral
Aug 11, 2026Morgan StanleymainOverweightOverweight
Jun 24, 2026Cantor Fitzgeraldinit—Overweight
Jun 17, 2026HC Wainwright & Co.reitBuyBuy
Mar 13, 2026HC Wainwright & Co.reitBuyBuy
Sep 16, 2025HC Wainwright & Co.reitBuyBuy

About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom

News

Your note

Sign in to keep a note on SLN — it syncs with the Stock Master app.

Institution ownership

SLN institution ownership
Holder% heldSharesValueReported
FMR, LLC7.58%4,710,81293.32MSep 29, 2026
Siren, L.L.C.4.65%2,887,86757.21MSep 29, 2026
Citadel Advisors Llc4.55%2,825,60155.98MSep 29, 2026
Redmile Group, LLC3.96%2,460,89448.75MSep 29, 2026
Tetragon Partners GP Ltd.3.92%2,436,05148.26MSep 29, 2026
Soleus Capital Management, L.P.3.84%2,385,70047.26MSep 29, 2026

Fund ownership

SLN fund ownership
Holder% heldSharesValueReported
Fidelity Select Portfolios-Select Biotechnology Portfolio2.66%1,654,90032.78MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.47%915,01018.13MAug 30, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund0.86%531,78810.53MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.80%500,0009.90MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund0.77%478,5109.48MAug 30, 2026
iShares Trust-iShares Biotechnology ETF0.47%289,9725.74MSep 29, 2026